secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxart, Inc. (VXRT)
CIK:        0000072444
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001437749-25-016447
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxart Q1 net loss $15.6M; COVID-19 Phase 2b screening underway, CFO appointed
------------------------------------------------------------------------------

- Net loss $15.6M ($0.07/shr) vs $24.4M ($0.14) prior year; revenue $20.9M from BARDA contract (vs $2.2M).
- Cash $41.9M; runway into Q1 2026; Project NextGen award up to $460.7M, $85.6M received to date.
- Screening for 10,000-person COVID-19 Phase 2b trial started; dosing expected Q2 2025 after stop work order lifted.
- Norovirus Phase 1 enrollment complete (60 participants); topline data mid-2025; avian flu vaccine 100% protective in ferret model.
- Jeroen Grasman appointed CFO effective May 19, 2025; Phillip Lee resigning as CFO for personal reasons.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/72444/000143774925016447/0001437749-25-016447-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/72444/000143774925016447/vxrt20250123_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-016447

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer